2012 Q4 Form 10-K Financial Statement
#000110465913016148 Filed on February 28, 2013
Income Statement
| Concept | 2012 Q4 | 2012 Q3 | 2012 Q2 |
|---|---|---|---|
| Revenue | $1.968M | $5.036M | $5.187M |
| YoY Change | 1620.31% | 2655.18% | 6303.21% |
| Cost Of Revenue | $2.322M | $2.119M | |
| YoY Change | |||
| Gross Profit | $2.714M | $3.068M | |
| YoY Change | |||
| Gross Profit Margin | 53.9% | 59.15% | |
| Selling, General & Admin | $4.190M | $1.257M | $914.0K |
| YoY Change | 143.6% | -25.19% | -54.07% |
| % of Gross Profit | 46.3% | 29.79% | |
| Research & Development | $2.515M | $148.7K | $209.9K |
| YoY Change | -62.48% | -98.71% | -98.11% |
| % of Gross Profit | 5.48% | 6.84% | |
| Depreciation & Amortization | $480.0K | $144.0K | $140.6K |
| YoY Change | 1500.0% | 303.59% | 251.6% |
| % of Gross Profit | 5.3% | 4.58% | |
| Operating Expenses | $2.515M | $1.405M | $1.124M |
| YoY Change | -62.48% | -87.78% | -89.89% |
| Operating Profit | -$3.635M | -$207.4K | $586.4K |
| YoY Change | -56.42% | -98.41% | -104.49% |
| Interest Expense | $81.23K | $501.0K | |
| YoY Change | -52.78% | -126.09% | |
| % of Operating Profit | 85.43% | ||
| Other Income/Expense, Net | -$91.21K | -$50.00K | |
| YoY Change | -600.0% | ||
| Pretax Income | $22.24M | -$379.8K | $35.42K |
| YoY Change | -434.44% | -97.02% | -100.24% |
| Income Tax | $90.00K | $866.00 | $0.00 |
| % Of Pretax Income | 0.4% | 0.0% | |
| Net Earnings | $22.22M | -$377.3K | $35.42K |
| YoY Change | -434.14% | -97.04% | -100.24% |
| Net Earnings / Revenue | 1129.31% | -7.49% | 0.68% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$1.602M | -$2.178M | |
| COMMON SHARES | |||
| Basic Shares Outstanding | 22.92M shares | ||
| Diluted Shares Outstanding | 22.92M shares |
Balance Sheet
| Concept | 2012 Q4 | 2012 Q3 | 2012 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $0.00 | $38.00M | $42.40M |
| YoY Change | -100.0% | -45.4% | 14.29% |
| Cash & Equivalents | $11.00K | $148.3K | $119.6K |
| Short-Term Investments | |||
| Other Short-Term Assets | $300.0K | $500.0K | $500.0K |
| YoY Change | -62.5% | -44.44% | -50.0% |
| Inventory | $2.810M | ||
| Prepaid Expenses | $313.0K | ||
| Receivables | $5.432M | ||
| Other Receivables | $0.00 | ||
| Total Short-Term Assets | $8.566M | $38.58M | $42.90M |
| YoY Change | -85.24% | -45.27% | 12.6% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $4.880M | $1.185M | $900.0K |
| YoY Change | 466.54% | 31.64% | -18.18% |
| Goodwill | $0.00 | ||
| YoY Change | |||
| Intangibles | $85.00K | ||
| YoY Change | |||
| Long-Term Investments | $3.400M | $3.400M | |
| YoY Change | 0.0% | 0.0% | |
| Other Assets | $302.3K | $0.00 | $100.0K |
| YoY Change | 202.29% | -100.0% | 0.0% |
| Total Long-Term Assets | $5.182M | $4.629M | $4.400M |
| YoY Change | 19.03% | 5.2% | -6.38% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $8.566M | $38.58M | $42.90M |
| Total Long-Term Assets | $5.182M | $4.629M | $4.400M |
| Total Assets | $13.75M | $43.21M | $47.30M |
| YoY Change | -77.96% | -42.31% | 10.51% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.994M | $2.005M | $3.800M |
| YoY Change | -36.71% | -66.59% | -39.68% |
| Accrued Expenses | $927.0K | $1.300M | $2.100M |
| YoY Change | -77.39% | -69.05% | -46.15% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $4.100M | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $7.600M | $10.50M | |
| YoY Change | 533.33% | 775.0% | |
| Total Short-Term Liabilities | $7.712M | $10.92M | $16.40M |
| YoY Change | 6.7% | -5.03% | 42.61% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $48.80M | $0.00 | $0.00 |
| YoY Change | 182.08% | -100.0% | -100.0% |
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $48.80M | $0.00 | $0.00 |
| YoY Change | 182.08% | -100.0% | -100.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $7.712M | $10.92M | $16.40M |
| Total Long-Term Liabilities | $48.80M | $0.00 | $0.00 |
| Total Liabilities | $10.59M | $10.92M | $16.40M |
| YoY Change | -56.87% | -64.42% | -47.44% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$43.80M | -$241.0M | |
| YoY Change | -79.84% | 14.43% | |
| Common Stock | |||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $0.00 | ||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$42.72M | $32.30M | $30.90M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $13.75M | $43.21M | $47.30M |
| YoY Change | -77.96% | -42.31% | 10.51% |
Cashflow Statement
| Concept | 2012 Q4 | 2012 Q3 | 2012 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $22.22M | -$377.3K | $35.42K |
| YoY Change | -434.14% | -97.04% | -100.24% |
| Depreciation, Depletion And Amortization | $480.0K | $144.0K | $140.6K |
| YoY Change | 1500.0% | 303.59% | 251.6% |
| Cash From Operating Activities | $21.98M | -$7.380M | -$7.050M |
| YoY Change | -301.1% | -41.34% | -49.24% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $240.0K | -$470.0K | -$10.00K |
| YoY Change | -442.86% | 327.27% | -96.88% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $10.00K | $0.00 | $0.00 |
| YoY Change | |||
| Cash From Investing Activities | $250.0K | -$470.0K | -$10.00K |
| YoY Change | -457.14% | 327.27% | -96.88% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -3.040M | 3.480M | 0.000 |
| YoY Change | 120.29% | -92.29% | -100.0% |
| NET CHANGE | |||
| Cash From Operating Activities | 21.98M | -7.380M | -7.050M |
| Cash From Investing Activities | 250.0K | -470.0K | -10.00K |
| Cash From Financing Activities | -3.040M | 3.480M | 0.000 |
| Net Change In Cash | 19.19M | -4.370M | -7.060M |
| YoY Change | -255.01% | -113.46% | -50.35% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $21.98M | -$7.380M | -$7.050M |
| Capital Expenditures | $240.0K | -$470.0K | -$10.00K |
| Free Cash Flow | $21.74M | -$6.910M | -$7.040M |
| YoY Change | -300.18% | -44.59% | -48.12% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2011 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
24062 | USD |
| CY2011 | bpax |
Proceeds From Issuance Of Common Stock By Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering
|
44961137 | USD |
| CY2011 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
23876370 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
67660011 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3471275 | USD |
| CY2010 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
48452644 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
48454658 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-22430893 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
19069983 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
8296786 | USD |
| CY2011 | us-gaap |
Interest Paid
InterestPaid
|
688000 | USD |
| CY2010 | us-gaap |
Interest Paid
InterestPaid
|
688000 | USD |
| CY2010 | bpax |
Noncash Investment
NoncashInvestment
|
65807 | USD |
| CY2011 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
21405 | USD |
| CY2009Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29858465 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
38155251 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
34794341 | USD |
| CY2012 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="MARGIN: 0in 0in 0pt 36.4pt; TEXT-INDENT: -29.9pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">                             </font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">DESCRIPTION OF BUSINESS</font></b></p> <p style="MARGIN: 0in 0in 0pt 36.4pt; TEXT-INDENT: -29.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">BioSante Pharmaceuticals, Inc. (the Company) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.  The Company’s products, either approved or in human clinical development, include: (1) LibiGel, once daily transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2) a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA, Inc. (Teva); (3) The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase II development; and (4) Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Meda, the Company’s licensee.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company’s lead product in development is LibiGel for the treatment of FSD, specifically HSDD, in postmenopausal women, for which there is no FDA-approved pharmaceutical product.  For the past several years, the Company focused its efforts on two Phase III LibiGel efficacy trials and a LibiGel Phase III cardiovascular and breast cancer safety study.  In December 2011, the Company announced results from its two Phase III LibiGel efficacy trials, which showed that the trials did not meet the co-primary or secondary endpoints.  Although LibiGel performed as predicted, increasing satisfying sexual events and sexual desire and decreasing distress associated with low desire, the placebo response in the two efficacy trials was greater than expected, and LibiGel’s results were not shown to be statistically different from the placebo.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Beginning in December 2011, the Company analyzed the data from its Phase III LibiGel efficacy trials, consulted with key opinion leaders in female sexual dysfunction, testosterone therapy and placebo effects, and met with representatives of the FDA.  As a result of this process, in June 2012 the Company announced a plan to initiate two new LibiGel Phase III efficacy trials.  The Company subsequently began the process of developing a protocol for the two new efficacy trials and applying for an FDA Special Protocol Assessment (SPA) agreement covering aspects of the two new efficacy trials.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In September 2012, the Company announced that the independent Data Monitoring Committee (DMC) completed its ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study and recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. At the time of the DMC review, there were 53 adjudicated cardiovascular events, with a lower than anticipated event rate of approximately 0.72 percent. In the same population of subjects, there were 27 breast cancers reported, a rate of approximately 0.37 percent, which is in line with the expected rate based on the ages of the subjects enrolled in the study. Given this latest review during which no specific or general safety issues were raised, and after extensive consideration, the Company also announced in September 2012 the conclusion of the LibiGel Phase III safety study effective immediately. Prior to the initiation of the LibiGel safety study in 2008, the FDA advised the Company that subjects in the cardiovascular event and breast cancer safety study were required to have a minimum average exposure in the safety study of 12 months prior to submitting a LibiGel new drug application (NDA), and prior to a potential FDA approval of LibiGel. As of the date of the conclusion of the safety study, subjects had been in the study for an average time of 24.5 months; more than 3,200 subjects had been in the study for more than one year and over 1,700 subjects had been enrolled for more than two years. With this ninth positive unblinded review of the study by the DMC, and over 7,400 women-years of exposure, the Company believes that adequate safety data of LibiGel use in menopausal women has been obtained.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company is continuing to develop a protocol for the two new LibiGel efficacy trials and intends to seek an FDA SPA agreement covering aspects of the two new efficacy trials.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On October 3, 2012, the Company entered into an agreement and plan of merger (the Merger Agreement) with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (ANI).  The Merger Agreement provides that, subject to the terms and conditions set forth in the Merger Agreement, ANI will merge with and into the Company, with the Company continuing as the surviving company (the Merger).  Following completion of the Merger, the current stockholders of ANI are expected to own approximately 53 percent of the outstanding shares of common stock of the combined company, and current stockholders of the Company are expected to own approximately 47 percent of the outstanding shares of common stock of the combined company, assuming the Company’s “net cash” as defined in the Merger Agreement and generally consisting of the Company’s cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the Merger, is $18.0 million.  The exchange ratios in the Merger are subject to potential adjustment as described in the Merger Agreement depending upon the amount of the Company’s net cash as of a determination date prior to the closing date of the Merger, but in no event will the current ANI stockholders own less than 50.1 percent (or the current Company stockholders own more than 49.9 percent) of the outstanding shares of common stock of the combined company.  The pending Merger with ANI is more fully described in Note 3, “Pending Merger with ANI.”</font></p></div> | |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
35173144 | USD |
| CY2012Q4 | us-gaap |
Assets
Assets
|
38769170 | USD |
| CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10593665 | USD |
| CY2010 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-1870916 | USD |
| CY2011Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
801147 | USD |
| CY2011Q4 | us-gaap |
Assets Current
AssetsCurrent
|
58026381 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
57225234 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
861364 | USD |
| CY2011Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
3405807 | USD |
| CY2011Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
86203 | USD |
| CY2011Q4 | us-gaap |
Assets
Assets
|
62379755 | USD |
| CY2011Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3150677 | USD |
| CY2011Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1597329 | USD |
| CY2011Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2479697 | USD |
| CY2011Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7227703 | USD |
| CY2011Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
17336760 | USD |
| CY2011Q4 | us-gaap |
Liabilities
Liabilities
|
24564463 | USD |
| CY2011Q4 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
255054440 | USD |
| CY2011Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-217239148 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
37815292 | USD |
| CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
62379755 | USD |
| CY2012Q4 | us-gaap |
Senior Notes Current
SeniorNotesCurrent
|
7883886 | USD |
| CY2012Q4 | us-gaap |
Liabilities
Liabilities
|
10593665 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
28175505 | USD |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
38769170 | USD |
| CY2011 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
335160 | USD |
| CY2010 | us-gaap |
Licenses Revenue
LicensesRevenue
|
115807 | USD |
| CY2011 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
44182260 | USD |
| CY2010 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
51870 | USD |
| CY2010 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
2306560 | USD |
| CY2010 | us-gaap |
Revenues
Revenues
|
2474237 | USD |
| CY2012 | us-gaap |
Revenues
Revenues
|
2300736 | USD |
| CY2011 | us-gaap |
Revenues
Revenues
|
435160 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
16888849 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-619148 | USD |
| CY2012 | us-gaap |
License Costs
LicenseCosts
|
95000 | USD |
| CY2010 | us-gaap |
License Costs
LicenseCosts
|
268750 | USD |
| CY2010 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
167986 | USD |
| CY2012 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
25472318 | USD |
| CY2011 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
51361990 | USD |
| CY2011 | us-gaap |
Interest Expense
InterestExpense
|
681573 | USD |
| CY2010 | us-gaap |
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
|
286000 | USD |
| CY2010 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
46082598 | USD |
| CY2012 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-4328468 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-121791 | USD |
| CY2010 | us-gaap |
Interest Expense
InterestExpense
|
688083 | USD |
| CY2011 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16397618 | shares |
| CY2010 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
244479 | USD |
| CY2010 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
12665 | USD |
| CY2011 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16397618 | shares |
| CY2010 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
39705502 | USD |
| CY2010 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-46196216 | USD |
| CY2010 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5940360 | USD |
| CY2011 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-51608504 | USD |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-27717739 | USD |
| CY2010 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-46196216 | USD |
| CY2011 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.15 | |
| CY2011 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.15 | |
| CY2010 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-4.21 | |
| CY2010 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-4.21 | |
| CY2010 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
10985291 | shares |
| CY2010 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
10985291 | shares |
| CY2010 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2014 | USD |
| CY2010 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
992757 | USD |
| CY2010 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
65529 | USD |
| CY2010 | bpax |
Stock Issued During Period Value Common Shares And Warrants
StockIssuedDuringPeriodValueCommonSharesAndWarrants
|
48452644 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
32442 | USD |
| CY2011 | bpax |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
24062 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1177683 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
44961137 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
204980 | USD |
| CY2011 | bpax |
Stock Issued During Period Value Common Shares And Warrants
StockIssuedDuringPeriodValueCommonSharesAndWarrants
|
23876370 | USD |
| CY2012 | bpax |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
211068 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
725625 | USD |
| CY2012 | bpax |
Stock Issued During Period Value Common Shares And Warrants
StockIssuedDuringPeriodValueCommonSharesAndWarrants
|
3260865 | USD |
| CY2011 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-367502 | USD |
| CY2010 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-4583 | USD |
| CY2011 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
148240 | USD |
| CY2011 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1177683 | USD |
| CY2011 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
204980 | USD |
| CY2010 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
992757 | USD |
| CY2010 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
65529 | USD |
| CY2010 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
65807 | USD |
| CY2011 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1682466 | USD |
| CY2010 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
365332 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
134103 | USD |
| CY2010 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
3142078 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-25283020 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-47870103 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-40097506 | USD |
| CY2010 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
3075 | USD |
| CY2011 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
719925 | USD |
| CY2010 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
63441 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-719925 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-60366 | USD |
| CY2011 | bpax |
Repayments Of Short Term Convertible Debt
RepaymentsOfShortTermConvertibleDebt
|
1234000 | USD |
| CY2011 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
32442 | USD |
| CY2010 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2014 | USD |
| CY2012Q2 | bpax |
Stockholders Equity Reverse Stock Split Conversion Ratio
StockholdersEquityReverseStockSplitConversionRatio
|
0.1667 | pure |
| CY2012Q2 | bpax |
Payments To Fractional Share Payout
PaymentsToFractionalSharePayout
|
658 | USD |
| CY2012 | dei |
Entity Registrant Name
EntityRegistrantName
|
BIOSANTE PHARMACEUTICALS INC | |
| CY2012 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001023024 | |
| CY2012 | dei |
Document Type
DocumentType
|
10-K | |
| CY2012 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-12-31 | |
| CY2012 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2012 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2012 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2012 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2013Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
24422240 | shares |
| CY2012Q2 | dei |
Entity Public Float
EntityPublicFloat
|
50100000 | USD |
| CY2012 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2012 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | |
| CY2009Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
15830394 | USD |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
19147122 | USD |
| CY2011 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
211494 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
10942720 | USD |
| CY2012Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
192732223 | USD |
| CY2012Q4 | bpax |
Percentage Of Provision Of Valuation Allowance To Reduce Deferred Tax Assets
PercentageOfProvisionOfValuationAllowanceToReduceDeferredTaxAssets
|
1.00 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.345 | pure |
| CY2012 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
122059 | USD |
| CY2010 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
179349 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
248632 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
41718 | USD |
| CY2012 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
423522 | USD |
| CY2011 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
424294 | USD |
| CY2010 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
338588 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1287453 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
557948 | USD |
| CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
391562 | USD |
| CY2011Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
426089 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
166386 | USD |
| CY2011Q1 | us-gaap |
Revenues
Revenues
|
57000 | USD |
| CY2011Q2 | us-gaap |
Revenues
Revenues
|
81003 | USD |
| CY2011Q3 | us-gaap |
Revenues
Revenues
|
182784 | USD |
| CY2011Q4 | us-gaap |
Revenues
Revenues
|
114373 | USD |
| CY2011Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14864420 | USD |
| CY2011Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11116323 | USD |
| CY2011Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11500053 | USD |
| CY2011Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6701465 | USD |
| CY2011Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1593557 | USD |
| CY2011Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1989103 | USD |
| CY2011Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1675268 | USD |
| CY2011Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1723562 | USD |
| CY2012Q1 | us-gaap |
Revenues
Revenues
|
114000 | USD |
| CY2012Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5153217 | USD |
| CY2011Q3 | us-gaap |
License Costs
LicenseCosts
|
50000 | USD |
| CY2012Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1831852 | USD |
| CY2011Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16442921 | USD |
| CY2012 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | item |
| CY2012 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | item |
| CY2010 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
64645 | USD |
| CY2012Q4 | bpax |
Fdic Insured Account Percentage Of Balance Insured
FDICInsuredAccountPercentageOfBalanceInsured
|
1.00 | pure |
| CY2012Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
3413762 | USD |
| CY2012 | bpax |
Number Of Board Members Designated By The Entity
NumberOfBoardMembersDesignatedByTheEntity
|
1 | item |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
63969813 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
4095269 | USD |
| CY2011Q4 | bpax |
Deferred Tax Assets Deferred Financing Costs
DeferredTaxAssetsDeferredFinancingCosts
|
7010462 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
8266610 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2754981 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
448140 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
86545275 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
86545275 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
72756414 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
3868769 | USD |
| CY2012Q4 | bpax |
Deferred Tax Assets Deferred Financing Costs
DeferredTaxAssetsDeferredFinancingCosts
|
8644459 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
9142943 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3028904 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
46506 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
97487995 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
97487995 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-17804934 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-1677276 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
-1537863 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
132491 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
20887582 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-15937695 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-1501377 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
-966941 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
133932 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
18272081 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-9562620 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-900827 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
-667308 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
66244 | USD |
| CY2012Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3635228 | USD |
| CY2012Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3987331 | USD |
| CY2011Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.22 | |
| CY2011Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.96 | |
| CY2011Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.73 | |
| CY2011Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.36 | |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.53 | |
| CY2012Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.36 | |
| CY2011Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13064942 | USD |
| CY2011Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13028207 | USD |
| CY2011Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8340710 | USD |
| CY2011Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17250676 | USD |
| CY2011Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14975231 | USD |
| CY2011Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12733691 | USD |
| CY2011Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6648906 | USD |
| CY2012Q1 | us-gaap |
License Costs
LicenseCosts
|
30000 | USD |
| CY2012Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6931935 | USD |
| CY2012Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10264477 | USD |
| CY2012Q2 | us-gaap |
Revenues
Revenues
|
108780 | USD |
| CY2012Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5398305 | USD |
| CY2012Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1948995 | USD |
| CY2012Q2 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2012Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7269453 | USD |
| CY2012Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7344116 | USD |
| CY2012Q3 | us-gaap |
Revenues
Revenues
|
110383 | USD |
| CY2012Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3822736 | USD |
| CY2012Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1546864 | USD |
| CY2012Q3 | us-gaap |
License Costs
LicenseCosts
|
50000 | USD |
| CY2012Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5334966 | USD |
| CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6121815 | USD |
| CY2012Q4 | us-gaap |
Revenues
Revenues
|
1967573 | USD |
| CY2012Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2514591 | USD |
| CY2012Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2901812 | USD |
| CY2012Q4 | us-gaap |
License Costs
LicenseCosts
|
15000 | USD |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| CY2012Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.16 | |
| CY2011 | us-gaap |
Licenses Revenue
LicensesRevenue
|
100000 | USD |
| CY2011 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
15000 | USD |
| CY2012Q4 | bpax |
Number Of Stockholder Approved Equity Based Compensation Plans
NumberOfStockholderApprovedEquityBasedCompensationPlans
|
2 | item |
| CY2012 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2012 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2011 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6981490 | USD |
| CY2011 | us-gaap |
License Costs
LicenseCosts
|
50000 | USD |
| CY2011 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
8326 | USD |
| CY2011 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-51608504 | USD |
| CY2011Q4 | bpax |
Fdic Insured Account Percentage Of Balance Insured
FDICInsuredAccountPercentageOfBalanceInsured
|
1.00 | pure |
| CY2011Q1 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2011Q2 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2011Q4 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-244956887 | USD |
| CY2012 | bpax |
Number Of Phase Iii Libi Gel Efficacy Trials
NumberOfPhaseIIILibiGelEfficacyTrials
|
2 | item |
| CY2012Q3 | bpax |
Number Of Adjudicated Cardiovascular Events At Time Of Data Monitoring Committee Review
NumberOfAdjudicatedCardiovascularEventsAtTimeOfDataMonitoringCommitteeReview
|
53 | item |
| CY2012Q3 | bpax |
Adjudicated Cardiovascular Event Rate
AdjudicatedCardiovascularEventRate
|
0.0072 | pure |
| CY2012Q3 | bpax |
Number Of Breast Cancers Reported In Sampling Population Under Data Monitoring Committee Review
NumberOfBreastCancersReportedInSamplingPopulationUnderDataMonitoringCommitteeReview
|
27 | item |
| CY2012Q3 | bpax |
Breast Cancer Rate Reported In Sampling Population Under Data Monitoring Committee Review
BreastCancerRateReportedInSamplingPopulationUnderDataMonitoringCommitteeReview
|
0.0037 | pure |
| CY2012Q3 | bpax |
Period Of Average Exposure In Safety Study Prior To Submission Of Nda And Potential Fda Approval
PeriodOfAverageExposureInSafetyStudyPriorToSubmissionOfNDAAndPotentialFDAApproval
|
P12M | |
| CY2012Q3 | bpax |
Average Time For Which Subjects Has Been In Study
AverageTimeForWhichSubjectsHasBeenInStudy
|
P24M15D | |
| CY2012 | bpax |
Term Of Arrangement From Date Of First Commercial Sale Of Product By Counterparty To Unrelated Party On Arms Length Price
TermOfArrangementFromDateOfFirstCommercialSaleOfProductByCounterpartyToUnrelatedPartyOnArmsLengthPrice
|
P10Y | |
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
378803 | USD |
| CY2012Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
15878 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1128644 | USD |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1078683 | USD |
| CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
502452 | USD |
| CY2012Q4 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
273132392 | USD |
| CY2012 | us-gaap |
Licenses Revenue
LicensesRevenue
|
1750000 | USD |
| CY2012 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
550736 | USD |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8229523 | USD |
| CY2012 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
258946 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
348019 | USD |
| CY2012 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
8539 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-27839530 | USD |
| CY2012 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.27 | |
| CY2012 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.27 | |
| CY2012 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
21757906 | shares |
| CY2012 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
21757906 | shares |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
725625 | USD |
| CY2012 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-1047225 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-492670 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-4418215 | USD |
| CY2012 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
7955 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
611193 | USD |
| CY2012 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
211068 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3260865 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
313435 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
13881052 | USD |
| CY2012 | bpax |
Payments For Fractional Share Payout
PaymentsForFractionalSharePayout
|
658 | USD |
| CY2012 | bpax |
Stock Issued During Period Value Fractional Share Adjustment
StockIssuedDuringPeriodValueFractionalShareAdjustment
|
-658 | USD |
| CY2012Q3 | bpax |
Number Of Reviews Of Studies By Data Monitoring Committee
NumberOfReviewsOfStudiesByDataMonitoringCommittee
|
9 | item |
| CY2011 | bpax |
Stock Issued During Period Common Shares And Warrants
StockIssuedDuringPeriodCommonSharesAndWarrants
|
711629 | shares |
| CY2010 | bpax |
Stock Issued During Period Common Shares And Warrants
StockIssuedDuringPeriodCommonSharesAndWarrants
|
2467212 | shares |
| CY2012Q4 | us-gaap |
Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
|
0 | USD |
| CY2012 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
929431 | USD |
